Skip to main content
search

RADNOR, PA – August 7, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, recently announced the release of D360™ version 25.5. This update enables scientists to generate data visualizations and perform analyses on dynamic, rule-defined subsets of data. This new capability allows scientists to divide up a dataset into series of compounds and perform separate analyses of each without manual intervention, allowing for optimal understanding of structure-activity relationships and the design of new therapeutic agents. 

The release also introduces improved support for sequence-based modalities, usability and display enhancements for data visualizations, workflow improvements, and new capabilities for small molecule analysis. 

Key Enhancements in D360 25.5:

  • Improved Support for Sequence-Based Modalities: The D360 Sequence Alignment Viewer now supports alignment on data subsets and allows for the realignment of sequences while preserving all display settings. This release also introduces updated default settings, including using the similarity matrix for alignment and turning on the “Allow Reference Shift” option by default. 
  • Data Visualization Updates: In addition to the dynamic data subset viewers, bar charts can now display series definitions based on text, date, and chemical structure data. The ability to add multiple lines to a chart has also been streamlined to reduce the number of clicks required. 
  • User Workflow Enhancements: The user interface has been improved with features like the highlighting of active filter gadgets and a toggle to show only active filters. The tagging gadget now supports multi-line text input. Queries can now use multiple text values with constraints like “contains,” “starts with,” and “ends with”. 
  • Small Molecule Analysis: Users can now perform transformation analyses on rule-defined subsets of records, as opposed to those explicitly flagged. Transformation analyses are also now cancellable when executed as a macro. 
  • API Enhancements and Deprecation: This release marks the end of support for API keys. All authentication mechanisms must now be switched to Service Tokens, which offer benefits such as customer-managed creation, built-in expiration dates, and greater simplicity for use in scripts. 

To learn more, visit www.certara.com/d360-scientific-informatics-platform 

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Certara contact:

Sheila Rocchio
[email protected]

Media contact:

Alyssa Horowitz
[email protected]